🇺🇸 FDA
Pipeline program

golidocitinib

ES-2025-244-02

Phase 2 small_molecule active

Quick answer

golidocitinib for IrAE is a Phase 2 program (small_molecule) at The First People's Hospital of Lianyungang with 1 ClinicalTrials.gov record(s).

Program details

Company
The First People's Hospital of Lianyungang
Indication
IrAE
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials